BEVERLY HILLS, Calif., March 15, 2004 (PRIMEZONE) -- The Biotech Stock Review issued the "Top 10 Performing Biotech Stocks" list, for the week ending 3/12/2004. For the prior three month period, the Top 10 Performing Biotech Stocks gained an average of 127%. During the same time-period the average Biotech stock gained 11%, vs. a gain of 2% for the NASDAQ 100.
1. Forbes Medi Tech Inc (Nasdaq:FMTI) $7.10 up 227%. 2. Keryx Biopharmaceuticals (Nasdaq:KERX) 12.73 up 168%. 3. Circle Group Holdings (OTCBB:CRGQ) $5.50 up 168%. 4. Northfield Laboratories (Nasdaq:NFLD) $13.58 up 165%. 5. Vion Pharmaceuticals (Nasdaq:VION) $3.43 up 128%. 6. Swiss Medica Inc. (OTCBB:SWME) $0.29 up 94%. 7. Aeterna Laboratoires Inc (Nasdaq:AELA) $5.67 up 89%. 8. Lipid Sciences (Nasdaq:LIPD) $6.10 up 88%. 9. Titan Pharmaceuticals (AMEX:TTP) $5.15 up 82%. 10. Dyax Corp (Nasdaq:DYAX) $12.97 up 66%.
A detailed 10 page version of this list with graphs can be found at:
http://www.biotechstockreview.com/biotech/Top10/index.htm
Top 10 Performing Biotech Stocks:
1. Forbes Medi Tech Inc (Nasdaq:FMTI) $7.10 up 227%. Forbes Medi-Tech Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of innovative prescription pharmaceutical and nutraceutical products for the prevention and treatment of cardiovascular and related diseases. Forbes' scientific platform is based on core sterol technology. By extracting plant sterols from by-products of the forestry industry, Forbes has developed cholesterol-lowering agents for use in pharmaceutical compounds, functional foods and dietary supplements. Web Site: http://www.forbesmedi.com/ Phone: (604) 689-5899
2. Keryx Biopharmaceuticals (Nasdaq:KERX) 12.73 up 168%. Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the treatment of diabetic nephropathy, for which Keryx recently commenced its U.S.-based Phase II/III clinical program. Additionally, Keryx is developing 3 clinical-stage oncology compounds including KRX-0401, a novel, oral, first- in-class AKT inhibitor in Phase II. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City. Web Site: http://www.keryxbiopharm.com/ Phone: (212) 531-5965
3. Circle Group Holdings (OTCBB:CRGQ) $5.50 up 168%. Circle Group Holdings is a pioneer of emerging technology companies. The Company provides small business infrastructure, funding and substantial intellectual capital to bring important and timely life-changing technologies to market through all early phases of the commercialization process. Its FiberGel Technologies subsidiary owns the worldwide rights to Z-Trim for all fields of use. Invented over many years by Outstanding Senior Research Scientist Dr. George Inglett at the United States Department of Agriculture (USDA), Z-Trim is a patented, zero calorie, multi-functional, fiber food ingredient from corn that lowers calories and fat in most foods without affecting taste or texture. Web Site: http://www.crgq.com/ and http://ztrim.com/ Phone: (847) 549-6002
4. Northfield Laboratories (Nasdaq:NFLD) $13.58 up 165%. Northfield Laboratories Inc. is engaged in the development of a safe and effective alternative to transfused blood for use in the treatment of acute blood loss. Its PolyHeme blood substitute product is a solution of chemically modified hemoglobin derived from human blood. PolyHeme simultaneously restores lost blood volume and hemoglobin levels and is designed for rapid, massive infusion. PolyHeme requires no cross-matching and is therefore immediately available and compatible with all blood types. It has an extended shelf life compared to blood. The Company purchases indated and outdated blood from The American Red Cross and Blood Centers of America for use as the starting material for PolyHeme. It uses a proprietary process of separation, filtration and chemical modification to produce PolyHeme. Web Site: http://www.northfieldlabs.com/ Phone: (847) 864-3500
5. Vion Pharmaceuticals (Nasdaq:VION) $3.43 up 128%. Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. Vion has two agents in clinical trials: Triapine(r), a potent inhibitor of a key step in DNA synthesis, and CLORETAZINE(TM) (VNP40101M), a unique sulfonyl hydrazine alkylating agent that has been designated as a fast track development program in relapsed or refractory acute myeloid leukemia by the U.S. Food and Drug Administration. Vion is also developing and has an option to license several heterocyclic hydrazones which have demonstrated potent anti-tumor activity in preclinical studies. Additional agents in preclinical studies include: KS119, a hypoxia-selective compound from the sulfonyl hydrazine class and TAPET(r), a modified Salmonella vector used to deliver anticancer agents directly to tumors. Web Site: http://www.vionpharm.com/ Phone: (203) 498-4210
6. Swiss Medica Inc. (OTCBB:SWME) $0.29 up 94%. Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. The company has built an experienced management team with over 100 years of blue chip experience in operational management, sales, marketing, e-commerce, corporate finance, mergers and acquisitions and business development. It's first all-stock bioscience acquisition is a patented, all natural, pain relief product from Germany, (called "024") that relieves pain and reduces swelling for those who suffer from chronic pain and arthritis. Topically applied pain relief is a worldwide multi-billion dollar market. 024 has received world-class endorsements the Norwegian/Swiss Olympic Ski Team the German Olympic Track & Field Team and other leading sports teams and hospitals. Web Site: http://www.swissmedica.com/ and http://www.024zone.com/ Phone: (877) 859-5200
7. Aeterna Laboratoires Inc (Nasdaq:AELA) $5.67 up 89%. AEterna Laboratories, along with its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including 2 already marketed and several other products at early and late- stage development in endocrinology, oncology and infectious diseases. Cetrorelix (Cetrotide(r)) is sold in the U.S. and Europe to the in vitro fertilization market, and is in Phase II clinical trials for endometriosis, uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido(r)) is sold for black fever and has successfully completed a Phase III trial in parasitic skin disease. Neovastat(r) is in a Phase III trial for non-small cell lung cancer. Several other clinical programs are underway with various potential development candidates, supported by a worldwide network of scientific and marketing partnerships. Furthermore, AEterna benefits from a discovery platform of 100,000 molecules which is generating promising new compounds. Web Site: http://www.aeterna.com Phone: (418) 652-8525
8. Lipid Sciences (Nasdaq:LIPD) $6.10 up 88%. Lipid Sciences, Inc. is a development-stage biotechnology company that is researching and developing products and processes intended to treat major medical conditions in which lipids, or fat components, play a key role. The Company's technologies are based on a process that selectively removes lipids from proteins. This delipidation process has the potential for far-reaching implications related to human health. It may provide an effective therapeutic effect on many infectious agents, including the viruses that cause AIDS, Hepatitis B and Hepatitis C, as well as reverse cardiovascular and cerebrovascular disease. Web Site: http://www.lipidsciences.com Phone: (925) 249-4000
9. Titan Pharmaceuticals (AMEX:TTP) $5.15 up 82%. Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases. The Company's product development programs focus on large pharmaceutical markets with significant unmet medical needs and commercial potential. It has eight products under development, with its internal resources focused primarily on clinical development of Spheramine for the treatment of late-stage Parkinson's disease; Pivanex for the treatment of non-small cell lung cancer; Gallium maltolate for the treatment of several cancers and bone-related disease associated with cancer, and Probuphine for the treatment of opiate addiction. Some of the Company's product development work is conducted through its two consolidated subsidiaries, Ingenex, Inc. and ProNeura, Inc. Web Site: http://www.titanpharm.com/ Phone: (650) 244-4990
10. Dyax Corp (Nasdaq:DYAX) $12.97 up 66%. Dyax Corp. is a biopharmaceutical company principally focused on the discovery, development and commercialization of antibody-, protein- and peptide-based therapeutic products. The Company uses its proprietary and patented technology, known as phage display, to identify compounds with the potential for the treatment of various diseases. Dyax is utilizing phage display technology to build a portfolio of product candidates that it plans to develop and commercialize either on its own or with others. On behalf of collaborators, Dyax also uses phage display technology to identify compounds that can be used in therapeutics, diagnostic imaging, the development of research reagents and in purifying and manufacturing biopharmaceuticals. Using phage display, the Company has developed DX-88, which was shown in-vitro to be a high-affinity, high-specificity inhibitor of human plasma kallikrein. Dyax has also developed DX-890, a novel human neutrophil elastase inhibitor. Web Site: http://www.dyax.com/ Phone: (617) 225-2500
Subscribe to our free newsletter and receive the "Top 10 Performing Biotech Stocks" every Monday, in your email. Visit: http://www.biotechstockreview.com/
About Top 10 Performing Biotech Stocks:
Top 10 Performing Biotech Stocks is a service of the Biotech Stock Review, the Internet PR Group and Wall Street Audio. Each week the Biotech Stock Review issues a Top Performing Biotech stock list, with percentages gained for the prior 3 months, along with a brief corporate description. It's a simple way for investors to keep up with the big movers in the Biotech Industry, regardless of their size.
Interviews with management of selected companies may be found at http://www.wallstreetaudio.com
The corporate descriptions above have been derived entirely from publicly available documents and/or sources including corporate press releases and/or SEC filings.
Certain statements attributable to individual companies within this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on various factors and assumptions that include such risks and uncertainties as the completion and profitability of sales reported; the market for homes generally and in areas where the Company operates; the availability and cost of land; changes in economic conditions and interest rates; an increase in raw materials and labor costs; consumer confidence; government regulation; and general economic, business and competitive factors, all or each of which may cause actual results to differ from the statements made in this press release.
About The Biotech Stock Review:
Circle Group Holdings and SwissMedica are clients of the Internet PR Group, Inc., the parent company of the Biotech Stock Review. Please see the disclaimer on the corporate profile for details as required by SEC rule 17b, as well as in the welcome letter to the newsletter.
Sign up for the monthly Biotech Stock Review newsletter and never miss the above Top Performer List by sending an email to: biotech@internetstockreview.com
To view the monthly Top Performing Biotech Stocks online, which is a list of the Top Performing stocks in the Biotech, Health Science and Nutraceutical industries, visit the Biotech Stock Review at:
http://www.biotechstockreview.com/biotech/Top10/index.htm
Each month, the Biotech Stock Review reaches the broadest base of investors who are interested in publicly traded Biotech, Health Science and Nutraceutical stocks, ensuring it reaches the right audience, at the right time.
Companies who wish to add a photo or logo to, or modify their corporate description, in either our monthly press release or weekly newsletter should call Roland Perry at the Biotech Stock Review at (310) 278-8016 or Todd Gilligan at (949) 497-6684.